Oncology Institute grants 33,133 RSUs to director

Kaushal Mohit reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Kaushal Mohit reported acquisition or exercise transactions in this Form 4 filing.

Oncology Institute, Inc. director Kaushal Mohit received a grant of 33,133 restricted stock units (RSUs) of common stock on July 27, 2026. Each RSU entitles him to one share of common stock upon settlement.

The RSUs vest in full at the company’s 2027 annual meeting of stockholders, subject to his continued service with the company on the vesting date. Following this award, his reported direct holdings total 205,716 shares of common stock.

Insider Trade Summary

Grant/Award: 33,133 shares

Grant/Award 1 txn

Insider Kaushal Mohit

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	33,133	$0.00	$0.00

Holdings After Transaction: Common Stock — 205,716 shares (Direct)

Footnotes (1)

1. F1. Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.

Key Figures

RSUs granted: 33,133.0000 shares Shares following transaction: 205,716.0000 shares Grant price per share: 0.0000 +3 more

6 metrics

RSUs granted 33,133.0000 shares Restricted stock units awarded to director Kaushal Mohit on 2026-07-27

Shares following transaction 205,716.0000 shares Director’s reported direct holdings after the RSU grant

Grant price per share 0.0000 Reported transaction price per share for the RSU grant

Transaction date 2026-07-27 Date of RSU grant to director Kaushal Mohit

Vesting reference year 2027 RSUs vest at Oncology Institute’s 2027 annual meeting of stockholders

RSU-to-share ratio 1 RSU : 1 share Each RSU entitles the holder to receive one share of common stock upon settlement

Key Terms

restricted stock units (RSUs), vest in full, continued service, annual meeting of stockholders

4 terms

restricted stock units (RSUs) financial

"Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

vest in full financial

"The RSUs vest in full on the date of the Issuer's 2027 annual meeting"

continued service financial

"subject to the Reporting Person's continued service with the Issuer on the vesting date"

annual meeting of stockholders financial

"on the date of the Issuer's 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Oncology Institute (TOI) report for director Kaushal Mohit?

Oncology Institute reported that director Kaushal Mohit received a grant of 33,133 restricted stock units (RSUs) on July 27, 2026. Each RSU represents the right to receive one share of common stock upon settlement, subject to vesting conditions.

How many RSUs were granted to Kaushal Mohit in the latest TOI Form 4?

Director Kaushal Mohit was granted 33,133 RSUs of Oncology Institute common stock. These RSUs were awarded at no stated cash price per share and will convert into the same number of common shares when they settle, once vesting is satisfied.

When do Kaushal Mohit’s RSUs reported by TOI vest?

The 33,133 RSUs vest in full at Oncology Institute’s 2027 annual meeting of stockholders. Vesting is conditioned on Mohit’s continued service with the company through that meeting date, after which the RSUs can settle into common stock.

What are Kaushal Mohit’s total TOI share holdings after this RSU grant?

After the reported RSU grant, director Kaushal Mohit is shown with 205,716 shares of Oncology Institute common stock held directly. This total reflects his ownership immediately following the award as disclosed in the Form 4 filing.

Was the TOI equity grant to Kaushal Mohit made under a Rule 10b5-1 trading plan?

The grant was not reported as made under a Rule 10b5-1 plan. The filing’s Rule 10b5-1 checkbox is left unchecked, and no footnote indicates that the transaction occurred pursuant to a pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/29/2026 - 06:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaushal Mohit

(Last) (First) (Middle)

C/O THE ONCOLOGY INSTITUTE

18000 STUDEBAKER RD, SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		A(1)		33,133	A	$0.00	205,716	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.

	/s/ Mark Hueppelsheuser, Attorney-in-Fact for Mohit Kaushal	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)